Author

Nohemí Salinas-Jazmín

Universidad Nacional Autónoma de MéxicoORCID 0000-0002-9870-8650Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Axel A. Sánchez-ÁlvareziD· 1 shared Ivonne López-Lerma· 1 shared José L. Medina‐FrancoiD· 1 shared Luis Córdova-BahenaiD· 1 shared Marco Antonio Velasco-VelázqueziD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

5 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Axel A. Sánchez-ÁlvarezORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Daclatasvir, a symmetric drug for an anti-symmetric target

Luis Córdova-Bahena, Axel A. Sánchez-Álvarez, Ivonne López-Lerma, Nohemí Salinas-Jazmín, José L. Medina‐Franco, Marco Antonio Velasco-Velázquez

This study identifies daclatasvir, an FDA-approved antiviral, as a potential PD-L1 inhibitor through computational methods, showing it binds stably to the PD-L1 homodimer.

Journal of the Mexican Chemical Society · Jan 1, 2026Peer-reviewedCancer Biology